Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.


home / news releases / NBIX - Neurocrine upgraded at Barclays despite Q1 earnings miss

NBIX - Neurocrine upgraded at Barclays despite Q1 earnings miss

Neurocrine Biosciences Inc.
Barclays has upgraded shares of Neurocrine Biosciences (NBIX) from equal weight to overweight while maintaining a price target of $110.Given yesterday's closing price, that assumes upside of ~20%.Yesterday, Neurocrine's Q1 earnings missed on both revenue and EPS.Analyst Carter Gould writes he sees the company's tardive dyskinesia therapy Ingrezza (valbenazine) returning to growth this quarter as more in-office doctor visits resume.He adds sales could grow $25M-$35M per quarter in the second half of the year.Gould is modeling Ingrezza sales of $1.08B for the year.Neurocrine shares are down 3.7% to $88.22 in morning trading.

For further details see:

Neurocrine upgraded at Barclays despite Q1 earnings miss
Stock Information
Company Name: Neurocrine Biosciences Inc.
Stock Symbol: NBIX
Market: NASDAQ
Website: neurocrine.com
Menu
NBIX NBIX Quote NBIX Short NBIX News NBIX Articles NBIX Message Board
Get NBIX Alerts

News, Short Squeeze, Breakout and More Instantly...